Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Clinical Cancer Research (Impact Factor: 8.19). 05/2010; 16(9):2688-95. DOI: 10.1158/1078-0432.CCR-09-3407
Source: PubMed

ABSTRACT A subgroup of human epidermal growth factor receptor 2 (HER2)-overexpressing breast tumors coexpresses p95HER2, a truncated HER2 receptor that retains a highly functional HER2 kinase domain but lacks the extracellular domain and results in intrinsic trastuzumab resistance. We hypothesized that lapatinib, a HER2 tyrosine kinase inhibitor, would be active in these tumors. We have studied the correlation between p95HER2 expression and response to lapatinib, both in preclinical models and in the clinical setting.
Two different p95HER2 animal models were used for preclinical studies. Expression of p95HER2 was analyzed in HER2-overexpressing breast primary tumors from a first-line lapatinib monotherapy study (EGF20009) and a second-line lapatinib in combination with capecitabine study (EGF100151). p95HER2 expression was correlated with overall response rate (complete + partial response), clinical benefit rate (complete response + partial response + stable disease > or =24 wk), and progression-free survival using logistic regression and Cox proportional hazard models.
Lapatinib inhibited tumor growth and the HER2 downstream signaling of p95HER2-expressing tumors. A total of 68 and 156 tumors from studies EGF20009 and EGF100151 were evaluable, respectively, for p95HER2 detection. The percentage of p95HER2-positive patients was 20.5% in the EGF20009 study and 28.5% in the EGF100151 study. In both studies, there was no statistically significant difference in progression-free survival, clinical benefit rate, and overall response rate between p95HER2-positive and p95HER2-negative tumors.
Lapatinib as a monotherapy or in combination with capecitabine seems to be equally effective in patients with p95HER2-positive and p95HER2-negative HER2-positive breast tumors.

Download full-text


Available from: Joaquín Arribas, Jul 06, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HER2 overexpression has been observed in 20-30% of breast cancer cases. In addition to main products of HER2 gene, there are other variations, of which, the most important one is Δ16HER2. In principle, although HER2 overexpression is the first step for carcinogenesis, it is not sufficient, and the main reason responsible for breast tumorigenesis is Δ16HER2. This onco-protein, which lacks exon 16, can form stable homodimers remaining active constitutively. Like Δ16HER2, 611-CTF, a specific HER2 carboxy-terminal fragment, expresses a constitutively active homodimers. Therefore, targeting of Δ16HER2 and 611-CTF is the most promising strategy for treating HER2+ breast cancer. Along with inhibitors of HER2 gene products, miRNAs are also novel candidates for treatment of breast malignancy. Several drugs, working against different domains of the HER2 receptor, have been presented for treatment of HER2 positive breast cancers and they can increase mortality in patients.
  • [Show abstract] [Hide abstract]
    ABSTRACT: An integrated teaching laboratory (ITL) is being built at the University of Colorado to provide interdisciplinary design and development experiences for engineering students beginning at the freshman level. The ITL will be fully operation in 1997 and will consist primarily of open space with portable lab stations that can be reconfigured to accommodate various types of experiments. Students from every discipline in the engineering college will work next to one another in the lab. The close proximity will foster interdisciplinary curiosity and cooperation, and encourage teamwork and creative problem-solving. The building is being designed with many sensors so that it can itself be part of experimentation that can range from environmental air analysis to water flow to electrical usage. This paper will specifically address the results of the pilot sections of the ITL First-Year Engineering Projects Course in which one section is focusing on speech processing in the design of systems that are controlled by speech
    Signals, Systems and Computers, 1994. 1994 Conference Record of the Twenty-Eighth Asilomar Conference on; 01/1994
  • [Show abstract] [Hide abstract]
    ABSTRACT: Charging of macro-particles is shown to occur due to the positive ion flux, in the growing plasma sheath, during the post arc current phase. A theoretical investigation of the influence of these strongly charged macro-particles, on the breakdown of vacuum circuit breakers, is presented. The trajectories of these positively charged particles during the recovery voltage phase is studied. Field emission from the cathode due to these particles is studied. Finally, the trajectories of emitted electrons are studied and breakdown probabilities discussed. The model proposed, gives new insight into the statistical nature of post arc breakdown in vacuum circuit breakers and especially, late breakdowns
    Discharges and Electrical Insulation in Vacuum, 2000. Proceedings. ISDEIV. XIXth International Symposium on; 02/2000